Aurinia LUPKYNIS™ (voclosporin) OKd for Lupus Nephritis

 - LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death -

- LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials

- LUPKYNIS is now commercially available in the U.S. -

- Multimedia components are available with this press release (link here) -

- Conference call to be hosted Monday, January 25, 2021, 8:30 a.m. ET -

The webcast can be accessed on the investor section of the Aurinia website at www.auriniapharma.com. To participate in the teleconference, please dial +1-877-407-9170 (Toll-free U.S. & Canada).

https://finance.yahoo.com/news/fda-approves-aurinia-pharmaceuticals-lupkynis-012400315.html